Regenerative medicine最新文献

Osteoarthritis (OA), a prevalent degenerative joint disease, poses significant global health implications and is characterized by progressive degradation of articular cartilage, resulting in debilitating pain and disability. Current treatments often provide only symptomatic relief or require multiple invasive open-joint procedures that are both costly and surgically complex. This review intends to evaluate key design considerations, drawing inspiration from clinically approved therapeutics and recent advances in the field that can truly unlock the potential of injectable hydrogels in cartilage tissue engineering. These include the choice of cargo, hydrogel architecture, and critical factors that are often overlooked in injectable hydrogels, such as ensuring integration with native tissue and restoring joint lubrication. The manuscript also addresses key barriers to clinical translation, including navigating stringent regulatory pathways and optimizing hydrogel performance to meet the mechanical and biological demands of the joint environment. Finally, the review outlines future research directions with emphasis on acellular off-the-shelf strategies, and personalized medicine approaches informed by advances in -omics and high-throughput screening data to accelerate the clinical translation of next-generation injectable hydrogels for effective cartilage repair.

Background: Neurotmesis leads to neuromuscular junction (NMJ) degeneration, muscle atrophy, and functional loss. While neurorrhaphy is standard, motor recovery is often incomplete. Heterologous fibrin biopolymer (HFB) shows potential as an adjunct, hence, we investigate HFB's late regenerative effects.

Material/methods: Twenty adult male Wistar rats (CEUA-FMB 1402/2021) were divided into Control (C), Denervated (D), Neurorrhaphy (N), and Neurorrhaphy + HFB (NB) groups. After 120 days, nerves and muscles were analyzed.

Results: NB (1355 ± 170.4) showed more intact axons than C (927 ± 170.4, p = .0026) and N (774 ± 158.2, p = .0002). NMJ morphology in NB was closer to C than N, with increased nAChR alpha-1 (NB vs. N p = .0428; NB vs C p = .0084) and Rapsyn (NB vs. N p = .0130; NB vs C p = .0053) expression. Muscle integrity in NB resembled C, exhibiting less atrophy (area: C vs. N p = .0002; NB vs. N p = .0117; perimeter: C vs. N p = .0002; NB vs. N p = .0114; central nuclei: C vs. N p = .0009; NB vs. N p = .0110) and fibrosis (C vs. N p = .0061; N vs. NB p = .0326) compared to N.

Conclusion: HFB associated with neurorrhaphy enhanced muscle and nerve regeneration, attenuating muscle atrophy and fibrosis.

Aim: To evaluate the effectiveness of a bioregenerative scaffold created from bone marrow aspirate, cancellous bone autograft, platelet-rich plasma, and autologous fibrin in treating complicated non-unions of the supracondylar femur, humeral shaft, and radius and ulna.

Methods & materials: Three patients with non-unions resulting from multiple surgical failures underwent bone stabilization along with the application of a novel bioregenerative scaffold. X-rays and subjective assessments were collected prior to surgery and at 6- and 12-months post-surgery.

Results: All non-unions demonstrated healing with adequate callus formation, as confirmed by radiological assessments. By 12 months, all patients were able to resume full weight-bearing activities or regain full range of motion and physical strength without pain. Statistical analysis revealed improvements across all assessment scales compared to pre-surgical values.

Conclusion: This approach offers a viable option for treating complex long bone non-unions after multiple surgical interventions.

Charcot-Marie-Tooth (CMT) disease refers to a diverse group of inherited and progressive neuropathies for which no approved treatments currently exist and management strategies remain limited to symptomatic interventions. Recent advances in gene therapy offer promising strategies to address CMT neuropathies. This review highlights key progress in developing gene silencing, replacement, or editing therapies for representative CMT types, and summarizes preclinical successes and translational challenges. Delivery technologies such as AAV vectors and nanoparticle systems have shown promise, but delivery limitations across the blood-nerve and -brain barriers, immune reactions and other potential toxicities, and scalability remain challenging. Advancing into the era of CMT treatments requires clinical readiness, which depends on optimizing therapeutic delivery, enhancing safety, and developing biomarkers for treatment monitoring.

Latest developments in the field of stem cell research and regenerative medicine were compiled from publicly available information and press releases from non-academic institutions in February 2025.

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in January 2025.

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in November 2024.

Background: This study aimed to compare the effects of different treatments on quality of life in knee osteoarthritis patients. It focused on three therapies: bone marrow aspirate concentrate (BMAC), platelet-rich plasma (PRP), and hyaluronic acid (HA).

Methodology: The trial was conducted at a single center with 175 patients over a 12-month period with the knee OA, KL grade II-IV. Outcomes were measured using the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) and SF-36 scales, which assess physical and emotional well-being. Linear mixed models (LMMs) were used to analyze which treatment had the most positive impact on quality of life.

Results: Patients treated with BMAC showed the most substantial improvement, particularly in physical health and mobility (p ≤ 0,001). PRP outperformed HA in some aspects, but BMAC consistently led to greater gains. The most notable enhancements were seen in areas like role limitations due to physical health and overall physical functioning.

Conclusions: The study suggested that BMAC treatment may contribute to improved quality of life in patients with knee osteoarthritis, particularly in terms of physical function. The correlation between WOMAC and SF-36 scores supports these findings, indicating a potential role for BMAC in enhancing mobility.

Clinical trial registration: NCT03825133 (ClinicalTrials.gov).

There is no established consensus or standardized method for the preparation of amniotic membrane extract (AME). Consequently, various preparation, preservation, and sterilization techniques have been employed. To obtain AME rich in bioactive components with high therapeutic efficacy, each step of the preparation process is of critical importance. The appropriate procurement of the amniotic membrane minimizes the risk of infection transmission and reduces inter- and intra-donor variability. For the subsequent extraction process, different approaches are utilized due to factors such as laboratory infrastructure variability and the lack of a standardized method. Although lyophilization has recently emerged as a prominent method for the long-term preservation of AME, further investigation is required to assess its impact on the biochemical composition and clinical efficacy of the membrane. In ophthalmology, in vitro, in vivo, and clinical studies indicate that AME supports corneal epithelial regeneration, suppresses inflammation, and is a well-tolerated therapeutic agent. Consequently, further studies are still needed to enhance the effective release of therapeutic components from the amniotic membrane, improve the quality and consistency of AME, and preserve its content over an extended period. Thus, the clinical application of AME-derived products in the form of eye drops will become more widespread in the future.